Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials
Authors
Keywords
Protein tyrosine phosphatase, Dephosphorylase, Allosteric regulation, Oncogenic protein, Tumor suppressor, SHP2 inhibitors, Cancer therapy
Journal
PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages 107966
Publisher
Elsevier BV
Online
2021-08-14
DOI
10.1016/j.pharmthera.2021.107966
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of Thalidomide-based PROTAC Small Molecules as the Highly Efficient SHP2 Degraders
- (2021) Xiangbo Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Novel PROTACs for degradation of SHP2 protein
- (2021) Mengzhu Zheng et al. BIOORGANIC CHEMISTRY
- Therapeutic potential of targeting SHP2 in human developmental disorders and cancers
- (2020) Dadong Shen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4
- (2020) Kunlin Yu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Molecular mechanism of SHP2 activation by PD-1 stimulation
- (2020) M. Marasco et al. Science Advances
- Immune checkpoint signaling and cancer immunotherapy
- (2020) Xing He et al. CELL RESEARCH
- Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
- (2020) Mingliang Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
- (2020) Xinrui Yuan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds
- (2020) Wenjie Guo et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
- (2020) Zhen-Dong Song et al. Acta Pharmaceutica Sinica B
- Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib
- (2020) Yuting Sun et al. CANCER RESEARCH
- Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation
- (2020) Guangya Zhu et al. CELL
- Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling
- (2020) Huai-Xiang Hao et al. CLINICAL CANCER RESEARCH
- Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders
- (2020) Kai Tang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
- (2020) Matthew J. LaMarche et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities – A comprehensive review
- (2020) Rati Kailash Prasad Tripathi et al. Chemical Biology & Drug Design
- Small‐Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview
- (2020) Rangan Mitra et al. ChemMedChem
- A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors
- (2020) Yihui Song et al. Acta Pharmaceutica Sinica B
- Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer
- (2019) Ming-Jenn Chen et al. PATHOLOGY RESEARCH AND PRACTICE
- Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors
- (2019) Jeffrey T. Bagdanoff et al. JOURNAL OF MEDICINAL CHEMISTRY
- 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
- (2019) Patrick Sarver et al. JOURNAL OF MEDICINAL CHEMISTRY
- Genetic abnormalities and pathophysiology of MDS
- (2019) Naoko Hosono International Journal of Clinical Oncology
- The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer
- (2019) Ling-juan He et al. OncoTargets and Therapy
- Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
- (2019) Javier Celis-Gutierrez et al. Cell Reports
- SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells
- (2019) Lei Jiang et al. Artificial Cells Nanomedicine and Biotechnology
- An allosteric inhibitor of SHP2 effectively targets PDGFRα-driven glioblastoma
- (2019) Bakhos A Tannous et al. NEURO-ONCOLOGY
- Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway
- (2019) Fan Yang et al. OncoTargets and Therapy
- Targeting SHP2 as a promising strategy for cancer immunotherapy
- (2019) Qianqian Liu et al. PHARMACOLOGICAL RESEARCH
- Dual Allosteric Inhibition of SHP2 Phosphatase
- (2018) Michelle Fodor et al. ACS Chemical Biology
- Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET
- (2018) Jacey J. Liu et al. JOURNAL OF HEPATOLOGY
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
- (2018) Leila Dardaei et al. NATURE MEDICINE
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis
- (2018) Ariella Zehender et al. Nature Communications
- SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
- (2018) Mingxia Zhao et al. Acta Pharmaceutica Sinica B
- Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
- (2018) Ricardo A. P. Pádua et al. Nature Communications
- Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
- (2018) Jonathan R. LaRochelle et al. Nature Communications
- Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors
- (2018) Pedro Torres-Ayuso et al. Cancer Discovery
- Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients
- (2017) Daimin Xiang et al. HEPATOLOGY
- The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)
- (2017) Fatima Ardito et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3
- (2017) Chen Qi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment
- (2017) Jingjing Xie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phosphorylation: Implications in Cancer
- (2017) Vishakha Singh et al. PROTEIN JOURNAL
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Responses to Cytokines and Interferons that Depend upon JAKs and STATs
- (2017) George R. Stark et al. Cold Spring Harbor Perspectives in Biology
- Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells
- (2017) Yu-Jing Sun et al. Oncotarget
- SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells
- (2017) Zhuqing Liu et al. Oncotarget
- Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798
- (2017) Xuemei Yang et al. Oncotarget
- TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy
- (2016) Xin-guang Liu et al. IMMUNOLOGICAL INVESTIGATIONS
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- (2016) Jorge Garcia Fortanet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
- (2016) B M Richine et al. LEUKEMIA
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- An increase in galectin-3 causes cellular unresponsiveness to IFN-γ-induced signal transduction and growth inhibition in gastric cancer cells
- (2016) Po-Chun Tseng et al. Oncotarget
- A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2
- (2016) Susanne B. Breitkopf et al. Scientific Reports
- Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2
- (2015) Cynthia M. Chio et al. BIOCHEMISTRY
- SHP2 sails from physiology to pathology
- (2015) Mylène Tajan et al. European Journal of Medical Genetics
- PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients
- (2015) Tao Han et al. JOURNAL OF HEPATOLOGY
- Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
- (2015) Severa Bunda et al. Nature Communications
- Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development
- (2015) Rong Deng et al. Oncotarget
- Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations
- (2014) Zhi-Hong Yu et al. BIOCHEMISTRY
- Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells
- (2014) K S Siveen et al. BRITISH JOURNAL OF CANCER
- The second-sphere residue T263 is important for the function and catalytic activity of PTP1B via interaction with the WPD-loop
- (2014) Peng Xiao et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Inhibition of IFN- -Induced STAT1 Tyrosine Phosphorylation by Human CMV Is Mediated by SHP2
- (2014) M. Baron et al. JOURNAL OF IMMUNOLOGY
- Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)
- (2014) Wei Qiu et al. BMC STRUCTURAL BIOLOGY
- Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma
- (2013) Jie Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities
- (2013) Wiljan J.A.J. Hendriks et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma
- (2013) L.B. Dong et al. GENETICS AND MOLECULAR RESEARCH
- SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer
- (2013) JIA GU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations
- (2013) Zhi-Hong Yu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Expression and Clinical Significance of SHP2 in Gastric Cancer
- (2013) S Dong et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2
- (2012) Hla Win-Piazza et al. CANCER LETTERS
- Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer
- (2012) Po-Chun Tseng et al. IMMUNOBIOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-β production
- (2012) Fei Meng et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo
- (2012) S C Nabinger et al. LEUKEMIA
- Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop
- (2012) Nicola Aceto et al. NATURE MEDICINE
- Low expression of SHP-2 is associated with less favorable prostate cancer outcomes
- (2012) Helena Tassidis et al. TUMOR BIOLOGY
- A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells
- (2011) L. Li et al. BLOOD
- Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
- (2011) Emilie A. Bard-Chapeau et al. CANCER CELL
- Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver
- (2011) Ma. Eugenia Díaz et al. CELLULAR SIGNALLING
- SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans
- (2011) Kun-Wei Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
- (2011) Wei-Tien Tai et al. JOURNAL OF HEPATOLOGY
- Helicobacter pyloriCagA Phosphorylation Status Determines the gp130-activated SHP2/ERK and JAK/STAT Signal Transduction Pathways in Gastric Epithelial Cells
- (2010) In Ohk Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3 Signaling
- (2010) T. Edouard et al. MOLECULAR AND CELLULAR BIOLOGY
- Cytokine signalling via gp130 in gastric cancer
- (2009) M. Howlett et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis
- (2009) G. Chan et al. BLOOD
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- The tyrosine phosphatase Shp2 (PTPN11) in cancer
- (2008) Gordon Chan et al. CANCER AND METASTASIS REVIEWS
- Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes
- (2008) Simone Martinelli et al. HUMAN MOLECULAR GENETICS
- Constitutively Active SHP2 Cooperates with HoxA10 Overexpression to Induce Acute Myeloid Leukemia
- (2008) Hao Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
- (2007) Marie Dance et al. CELLULAR SIGNALLING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More